Mitocin-C
Mitocin-C Uses, Dosage, Side Effects, Food Interaction and all others data.
Mitocin-C is an antineoplastic antibiotic which is enzymatically reduced to its active metabolite within susceptible cells. The active metabolite appears to cause cross-linking of DNA (primarily with guanine and cytosine pairs). It is also active against gm+ve bacteria and some viruses.
Mitocin-C is one of the older chemotherapy drugs, which has been around and in use for decades. It is an antibiotic which has been shown to have antitumor activity. Mitocin-C selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mitocin-C has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
| Trade Name | Mitocin-C |
| Availability | Prescription only |
| Generic | Mitomycin |
| Mitomycin Other Names | Ametycine, Mitamycin, Mitocin-C, Mitomycin, Mitomycin C |
| Related Drugs | Keytruda, capecitabine, pembrolizumab, fluorouracil, doxorubicin, cisplatin, Opdivo, nivolumab, gemcitabine, everolimus |
| Type | |
| Formula | C15H18N4O5 |
| Weight | Average: 334.3272 Monoisotopic: 334.127719706 |
| Groups | Approved |
| Therapeutic Class | Cytotoxic Chemotherapy |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
This is used for Diabetic foot infections; Chronic lymphatic leukaemia; Chronic myelogenous leukaemia; Gastric, Colorectal, Lung, Pancreatic, Cervix, Endometrium, Breast, Bladder, Head & neck carcinoma.
Mitocin-C is also used to associated treatment for these conditions: Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, Breast Cancer, Cancer, Anal, Cancer, Bladder, Cervical Cancers, Head and Neck Carcinoma, Mesothelioma, Non-Small Cell Lung Carcinoma (NSCLC), Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
How Mitocin-C works
Mitocin-C is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitocin-C is cell cycle phase-nonspecific.
Dosage
Mitocin-C dosage
Solid tumours Suggested regimen: Initial: 10-20 mg/m2; may repeat 6-8 wkly depending on blood count. Do not repeat if leucocyte and platelet counts are below acceptable levels. Do not re-administer if the nadir of the leucocyte count is <2,000 cells/mm3
Intravesical Superficial bladder tumours: Instill 10-40 mg 1 -3 times/wk for a total of 20 doses
Prevention of recurrent bladder tumours: Instill 20 mg 2 wkly or 40 mg 1-3-mthly.
Intravenous: Reconstitute by adding 10, 40 or 80 mL of sterile water for inj to a vial labeled as containing 5, 20, or 40 mg respectively, to provide a soln containing approx 0.5 mg/mL. The vial should be shaken to enhance dissolution. If the powd for inj does not dissolve immediately, allow the vial to stand at room temp until complete dissolution occurs.
Side Effects
Hemolytic uremic syndrome (<15%), Myelosuppression (64%), Nausea/ vomiting (14%), Fever (14%), Stomatitis (4%), Increased serum creatinine (2%), Mucous membrane toxicity (4%) , Fatigue, Pulmonary toxicity, Dyspnea, Cystitis, Interstitial fibrosis, Nephrotoxicity, Amenorrhea, Alopecia, Myelosuppression, haemolytic-uraemic syndrome.
Toxicity
Oral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30 mg/kg. Symptoms of overdose include nausea and vomiting.
Precaution
Repeated haematologic studies are necessary during treatment and for at least 7 wk after discontinuation of the drug. Discontinue use when the leucocyte count decreases to <4000/mm3 or the platelet count decreases to <150,000/mm3 or if a progressive decline in either occurs. Monitor patient for signs of renal or pulmonary toxicity.
Interaction
Increased incidence of cardiotoxicity with doxorubicin.
Food Interaction
No interactions found.Mitocin-C Drug Interaction
Moderate: doxorubicinMinor: ciprofloxacin, levofloxacinUnknown: charcoal, amoxicillin, RHO Immunoglobulin , lorazepam, amoxicillin / clavulanate, citalopram, sulfamethoxazole / trimethoprim, glucose, diltiazem, iodine / potassium iodide, pregabalin, metoprolol, metoprolol, mirabegron, acetaminophen, cholecalciferol, ondansetron
Mitocin-C Disease Interaction
Major: infections, bleeding disorders, myelosuppression, renal dysfunction
Elimination Route
Erratic.
Half Life
8-48 min
Elimination Route
Approximately 10% of a dose of mitomycin is excreted unchanged in the urine.
Pregnancy & Breastfeeding use
Pregnancy category- D
Contraindication
Hypersensitivity. Patient with platelet counts <100,000/mm3, leukocyte counts <4,000/mm3 or serum creatinine concentration >1.7 mg/dL. Patient with substantial prolongation of prothrombin time or bleeding time, coagulation disorders, increased bleeding tendency. Pregnancy and lactation.
Storage Condition
Powder for injection: Store between 15-30°C. Protect from light.
Reconstituted solution: Stable for 1 wk when stored between 15-25°C and 2 wk when stored between 2-8°C.
Innovators Monograph
You find simplified version here Mitocin-C
Mitocin-C contains Mitomycin see full prescribing information from innovator Mitocin-C Monograph, Mitocin-C MSDS, Mitocin-C FDA label
